Novartis Pharmaceuticals Corp. is continuing its operational changes, meaning more than 200 New Jersey workers are likely to lose their jobs, the company confirmed Tuesday.
Novartis filed a federal WARN notice with the state Department of Labor and Workforce Development stating that it would be restructuring the geographic footprint of its global development operations department, ceasing operations of two lines, data management and statistical programming.
As a result, 204 positions at the company’s East Hanover headquarters are scheduled to be eliminated by July 28.
“Last year, Novartis created the global drug development function to strengthen our ability to deliver breakthrough medicines for patients,” the company told NJBIZ in an emailed statement. “As part of this integration, we will be consolidating our data operations organization to our global development site in Hyderabad, India, which allows us to improve efficiencies through increased harmonization and standardization.
“Regrettably, as a result, approximately 250 positions in the United States (204 of which are in New Jersey) are expected to be impacted by this realignment.”
The Novartis statement did say some 40 manufacturing positions would be added at its Morris Plains facility, however.
“The United States continues to play a significantly large role in our business, and we remain committed to our research, facilities and headquarters within New Jersey and several other locations in the United States,” the company said.
The WARN notice said affected employees would receive severance and various benefits, and would be eligible to apply for other positions within the company.
WARN notices normally cover mass layoffs or facility closings as part of the Worker Adjustment and Retraining Notification Act of 1989.